These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 30244872)

  • 1. Dynamic changes of circulating miRNAs induced by the Ebola virus vaccine VSV-EBOV.
    Fischer T; Spohn M; Olearo F; Zinser ME; Kasonta R; Stubbe HC; Rechtien A; Ly ML; Schmiedel S; Lohse AW; Grundhoff A; ; Addo MM; Dahlke C
    Vaccine; 2018 Nov; 36(46):7083-7094. PubMed ID: 30244872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiviral Innate Responses Induced by VSV-EBOV Vaccination Contribute to Rapid Protection.
    Menicucci AR; Jankeel A; Feldmann H; Marzi A; Messaoudi I
    mBio; 2019 May; 10(3):. PubMed ID: 31138743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.
    Lázaro-Frías A; Gómez-Medina S; Sánchez-Sampedro L; Ljungberg K; Ustav M; Liljeström P; Muñoz-Fontela C; Esteban M; García-Arriaza J
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29514907
    [No Abstract]   [Full Text] [Related]  

  • 4. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial.
    Huttner A; Dayer JA; Yerly S; Combescure C; Auderset F; Desmeules J; Eickmann M; Finckh A; Goncalves AR; Hooper JW; Kaya G; Krähling V; Kwilas S; Lemaître B; Matthey A; Silvera P; Becker S; Fast PE; Moorthy V; Kieny MP; Kaiser L; Siegrist CA;
    Lancet Infect Dis; 2015 Oct; 15(10):1156-1166. PubMed ID: 26248510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Vesicular Stomatitis Virus-Ebola Virus Postexposure Treatment in Rhesus Macaques Infected With Ebola Virus Makona.
    Marzi A; Hanley PW; Haddock E; Martellaro C; Kobinger G; Feldmann H
    J Infect Dis; 2016 Oct; 214(suppl 3):S360-S366. PubMed ID: 27496978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia.
    Dolzhikova IV; Zubkova OV; Tukhvatulin AI; Dzharullaeva AS; Tukhvatulina NM; Shcheblyakov DV; Shmarov MM; Tokarskaya EA; Simakova YV; Egorova DA; Scherbinin DN; Tutykhina IL; Lysenko AA; Kostarnoy AV; Gancheva PG; Ozharovskaya TA; Belugin BV; Kolobukhina LV; Pantyukhov VB; Syromyatnikova SI; Shatokhina IV; Sizikova TV; Rumyantseva IG; Andrus AF; Boyarskaya NV; Voytyuk AN; Babira VF; Volchikhina SV; Kutaev DA; Bel'skih AN; Zhdanov KV; Zakharenko SM; Borisevich SV; Logunov DY; Naroditsky BS; Gintsburg AL
    Hum Vaccin Immunother; 2017 Mar; 13(3):613-620. PubMed ID: 28152326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ebola vaccine trials: progress in vaccine safety and immunogenicity.
    Matz KM; Marzi A; Feldmann H
    Expert Rev Vaccines; 2019 Dec; 18(12):1229-1242. PubMed ID: 31779496
    [No Abstract]   [Full Text] [Related]  

  • 8. Single low-dose VSV-EBOV vaccination protects cynomolgus macaques from lethal Ebola challenge.
    Marzi A; Reynolds P; Mercado-Hernandez R; Callison J; Feldmann F; Rosenke R; Thomas T; Scott DP; Hanley PW; Haddock E; Feldmann H
    EBioMedicine; 2019 Nov; 49():223-231. PubMed ID: 31631035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The vesicular stomatitis virus-based Ebola virus vaccine: From concept to clinical trials.
    Suder E; Furuyama W; Feldmann H; Marzi A; de Wit E
    Hum Vaccin Immunother; 2018; 14(9):2107-2113. PubMed ID: 29757706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-dependent T-cell Dynamics and Cytokine Cascade Following rVSV-ZEBOV Immunization.
    Dahlke C; Kasonta R; Lunemann S; Krähling V; Zinser ME; Biedenkopf N; Fehling SK; Ly ML; Rechtien A; Stubbe HC; Olearo F; Borregaard S; Jambrecina A; Stahl F; Strecker T; Eickmann M; Lütgehetmann M; Spohn M; Schmiedel S; Lohse AW; Becker S; Addo MM;
    EBioMedicine; 2017 May; 19():107-118. PubMed ID: 28434944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress in Elucidating Potential Markers and Mechanisms of Rapid Protection Conferred by the VSV-Vectored Ebola Virus Vaccine.
    Wong G
    mBio; 2019 Jul; 10(4):. PubMed ID: 31311887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detectable Vesicular Stomatitis Virus (VSV)-Specific Humoral and Cellular Immune Responses Following VSV-Ebola Virus Vaccination in Humans.
    Poetsch JH; Dahlke C; Zinser ME; Kasonta R; Lunemann S; Rechtien A; Ly ML; Stubbe HC; Krähling V; Biedenkopf N; Eickmann M; Fehling SK; Olearo F; Strecker T; Sharma P; Lang KS; Lohse AW; Schmiedel S; Becker S; ; Addo MM
    J Infect Dis; 2019 Jan; 219(4):556-561. PubMed ID: 30452666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlates of vaccine-induced protective immunity against Ebola virus disease.
    Medaglini D; Santoro F; Siegrist CA
    Semin Immunol; 2018 Oct; 39():65-72. PubMed ID: 30041831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Open-label phase I clinical trial of Ad5-EBOV in Africans in China.
    Wu L; Zhang Z; Gao H; Li Y; Hou L; Yao H; Wu S; Liu J; Wang L; Zhai Y; Ou H; Lin M; Wu X; Liu J; Lang G; Xin Q; Wu G; Luo L; Liu P; Shentu J; Wu N; Sheng J; Qiu Y; Chen W; Li L
    Hum Vaccin Immunother; 2017 Sep; 13(9):2078-2085. PubMed ID: 28708962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EBOLA VACCINE. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain.
    Marzi A; Robertson SJ; Haddock E; Feldmann F; Hanley PW; Scott DP; Strong JE; Kobinger G; Best SM; Feldmann H
    Science; 2015 Aug; 349(6249):739-42. PubMed ID: 26249231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ebola Virus Disease Survivors Show More Efficient Antibody Immunity than Vaccinees Despite Similar Levels of Circulating Immunoglobulins.
    Koch T; Rottstegge M; Ruibal P; Gomez-Medina S; Nelson EV; Escudero-Pérez B; Pillny M; Ly ML; Koundouno FR; Bore JA; Magassouba N; Dahlke C; Günther S; Carroll MW; Addo MM; Muñoz-Fontela C
    Viruses; 2020 Aug; 12(9):. PubMed ID: 32825479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High dose of vesicular stomatitis virus-vectored Ebola virus vaccine causes vesicular disease in swine without horizontal transmission.
    Morozov I; Monath TP; Meekins DA; Trujillo JD; Sunwoo SY; Urbaniak K; Kim IJ; Narayanan SK; Indran SV; Ma W; Wilson WC; O'Connor C; Dubey S; Troth SP; Coller BA; Nichols R; Martin BK; Feldmann H; Richt JA
    Emerg Microbes Infect; 2021 Dec; 10(1):651-663. PubMed ID: 33719915
    [No Abstract]   [Full Text] [Related]  

  • 18. Randomized, Blinded, Dose-Ranging Trial of an Ebola Virus Glycoprotein Nanoparticle Vaccine With Matrix-M Adjuvant in Healthy Adults.
    Fries L; Cho I; Krähling V; Fehling SK; Strecker T; Becker S; Hooper JW; Kwilas SA; Agrawal S; Wen J; Lewis M; Fix A; Thomas N; Flyer D; Smith G; Glenn G
    J Infect Dis; 2020 Jul; 222(4):572-582. PubMed ID: 31603201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus.
    Wang D; Raja NU; Trubey CM; Juompan LY; Luo M; Woraratanadharm J; Deitz SB; Yu H; Swain BM; Moore KM; Pratt WD; Hart MK; Dong JY
    J Virol; 2006 Mar; 80(6):2738-46. PubMed ID: 16501083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV.
    Ehrhardt SA; Zehner M; Krähling V; Cohen-Dvashi H; Kreer C; Elad N; Gruell H; Ercanoglu MS; Schommers P; Gieselmann L; Eggeling R; Dahlke C; Wolf T; Pfeifer N; Addo MM; Diskin R; Becker S; Klein F
    Nat Med; 2019 Oct; 25(10):1589-1600. PubMed ID: 31591605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.